 Home > Active Ingredient News > Blood System > Clin Cancer Res: Long-term follow-up results of Venetog monotherapy for relapsed/refractory non-Hodgkin's lymphoma

Clin Cancer Res: Long-term follow-up results of Venetog monotherapy for relapsed/refractory non-Hodgkin's lymphoma

 Last Update: 2021-09-12
 Source: Internet
 Author: User

Tags

non polar solvents

lipitor 20 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Overexpression of the anti-apoptotic protein B-cell lymphoma /leukemia-2 (BCL-2) provides a survival advantage for malignant B-cells, and is involved in tumorigenesis, disease progression, and chemotherapy resistance of B-cell malignancies

Lymphoma Venetoclax (Venetoclax) is an oral selective BCL-2 inhibitor that has been approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

In a phase 1 clinical trial of Venetog for relapsed/refractory NHL, the overall objective response rate (ORR) was as high as 44% .

A total of 106 patients received Venetog (in increasing doses from 200 mg to 1200 mg) monotherapy until the disease progressed or intolerable toxicity appeared

The treatment response of each subgroup

After a median follow-up of 38.

The median PFS for all patients was 5.

Duration of remission (A) and PFS (B) in patients with MCL and FL

Hematological AEs of all grades are uncommon : neutropenia (19%), anemia (19%), and thrombocytopenia (17%).

Hematology AEs of all levels are uncommon

In summary, in the FL, MCL, WM, and MZL subgroups, Venetog monotherapy can achieve long-lasting remission (especially in patients with complete remission), and the safety is controllable

In the FL, MCL, WM, and MZL subgroups, Venetog monotherapy can achieve lasting remission (especially in patients with complete remission), and the safety is controllable in the FL, MCL, WM, and MZL subgroups , Venetog monotherapy can obtain lasting remission (especially in patients with complete remission), and the safety is controllable

Original source:

Matthew S.

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.